Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.64 USD
Change Today -0.06 / -3.53%
Volume 248.4K
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

caladrius biosciences inc (CLBS) Snapshot

Open
$1.73
Previous Close
$1.70
Day High
$1.74
Day Low
$1.60
52 Week High
11/17/14 - $7.22
52 Week Low
08/7/15 - $1.10
Market Cap
90.8M
Average Volume 10 Days
235.9K
EPS TTM
$-1.59
Shares Outstanding
55.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CALADRIUS BIOSCIENCES INC (CLBS)

Related News

No related news articles were found.

caladrius biosciences inc (CLBS) Related Businessweek News

No Related Businessweek News Found

caladrius biosciences inc (CLBS) Details

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. Caladrius Biosciences, Inc. has a collaboration agreement with TrakCel Ltd. to implement cell therapy process management and supply chain integration technology. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.

182 Employees
Last Reported Date: 03/2/15
Founded in 1980

caladrius biosciences inc (CLBS) Top Compensated Officers

Chief Technology Officer, Chief Scientific Of...
Total Annual Compensation: $418.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $445.2K
Compensation as of Fiscal Year 2014.

caladrius biosciences inc (CLBS) Key Developments

Caladrius Biosciences, Inc. Reports Unaudited Earnings Results for the Second Quarter Ended June 30, 2015; Reports Impairment of Intangible Assets for the Second Quarter Ended June 30, 2015

Caladrius Biosciences, Inc. reported unaudited earnings results for the second quarter ended June 30, 2015. For the quarter, the company reported total revenue was approximately $5.9 million compared to $4.5 million a year ago, an increase of 31%, which was primarily due to higher reported Clinical Services revenues at PCT. Total non-GAAP adjusted revenue, which excludes the impact of deferred revenue adjustments, was approximately $5.0 million compared to $5.3 million a year ago. Net loss was approximately $17.2 million compared to net loss of $12.8 million a year ago. Net loss excluding non-cash charges was $26.1 million, compared with $19.4 million a year ago. Net loss for Second Quarter 2015 included the impact of changes in the company's ischemic repair program. The company reported impairment of intangible assets of $9.4 million for the second quarter ended June 30, 2015.

Caladrius Biosciences, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Caladrius Biosciences, Inc. announced that they will report Q2, 2015 results at 11:30 AM, GMT Standard Time on Aug 06, 2015

Caladrius Biosciences, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Caladrius Biosciences, Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLBS:US $1.64 USD -0.06

CLBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.13 USD 0.00
Cesca Therapeutics Inc $0.66 USD -0.03
Cytori Therapeutics Inc $0.35 USD -0.0267
International Stem Cell Corp $3.70 USD -0.10
StemCells Inc $0.47 USD +0.0088
View Industry Companies
 

Industry Analysis

CLBS

Industry Average

Valuation CLBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CALADRIUS BIOSCIENCES INC, please visit www.neostem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.